Treatment Reference Page

The following individuals and published works were originally referenced in "Understanding Treatment Options in Cutaneous Lymphoma"  from which this content was drawn.

1.    Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.

2.    Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.

3.    Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs. 2010;70(3):273-286.

4.    Bloom T, Kuzel TM, Querfeld C, Guitart J, Rosen ST. Cutaneous T-cell lymphomas: a review of new discoveries and treatments. Curr Treat Options Oncol. 2012;13(1):102-121.

5.    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: NHL (Mycosis Fungoides and S├ęzary Syndrome). 2013. http://cutaneouslymphoma.stanford.edu/docs/nhl_1.2014_MFSS.pdf.

6.    Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003;49(1):35-49.

7.    Whittaker S, Ortiz P, Dummer R, et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol. 2012;167(3):678-687.

8.    Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998;134(8):949-954.

9.    Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther. 2003;16(4):283-287.

10.    Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther. 2003;16(4):299-302.

11.    Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25-32.

12.    Apisarnthanarax N, Wood GS, Stevens SR, et al. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. Arch Dermatol. 2012;148(5):613-620.

13.    Poligone B, Heald P. Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard. Dermatol Clin. 2010;28(3):501-510.

14.    Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol. 2006;16(4):391-393.

15.    Martinez-Gonzalez MC, Verea-Hernando MM, Yebra-Pimentel MT, Del Pozo J, Mazaira M, Fonseca E. Imiquimod in mycosis fungoides. Eur J Dermatol. 2008;18(2):148-152.

16.    Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010;62(13):1285-1298.

17.    Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol. 2012;92(3):258-263.

18.    Schadt CR. Topical and oral bexarotene. Dermatol Ther. 2013;26(5):400-403.

19.    Zandi S, Kalia S, Lui H. UVA1 phototherapy: a concise and practical review. Skin Therapy Lett. 2012;17(1):1-4.

20.    Ponte P, Serrao V, Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol. 2010;24(6):716-721.

21.    Pothiawala SZ, Baldwin BT, Cherpelis BS, Lien MH, Fenske NA. The role of phototherapy in cutaneous T-cell lymphoma. J Drugs Dermatol. 2010;9(7):764-772.

22.    Husken AC, Tsianakas A, Hensen P, et al. Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol. 2012;26(1):71-78.

23.    Booken N, Weiss C, Utikal J, Felcht M, Goerdt S, Klemke CD. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sezary syndrome. 
J Dtsch Dermatol Ges. 2010;8(6):428-438.

24.    El-Mofty M, El-Darouty M, Salonas M, et al. Narrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right-left comparative study. Photodermatol Photoimmunol Photomed. 2005;21(6):281-286.

25.    Morris SL. Skin lymphoma. Clin Oncol (R Coll Radiol). 2012;24(5):371-385.

26.    Piccinno R, Caccialanza M, Cuka E, Recalcati S. Localized conventional radiotherapy in the treatment of mycosis fungoides: our experience in 100 patients. J Eur Acad Dermatol Venereol. 2013;[Epub ahead of print].

27.    Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002;47(3):364-370.

28.    Klein RS, Dunlop JD, Samimi SS, et al. Improvement in peripheral blood disease burden in patients with Sezary syndrome and leukemic mycosis fungoides after total skin electron beam therapy. J Am Acad Dermatol. 2013;68(6):972-977.

29.    Maingon P, Truc G, Dalac S, et al. Radiotherapy of advanced mycosis fungoides: indications and results of total skin electron beam and photon beam irradiation. Radiother Oncol. 2000;54(1):73-78.

30.    Micaily B, Campbell O, Moser C, Vonderheid EC, Brady LW. Total skin electron beam and total nodal irradiation of cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 1991;20(4):809-813.

31.    Micaily B, Moser C, Vonderheid EC, et al. The radiation therapy of early stage cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 1990;18(6):1333-1339.

32.    Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. 
J Am Acad Dermatol. 2013;69(4):537-543.

33.    Hallahan DE, Griem ML, Griem SF, et al. Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up. J Clin Oncol. 1988;6(7):1177-1183.

34.    Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000;43(1 Pt 1):54-60.

35.    Winkler CF, Sausville EA, Ihde DC, et al. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. J Clin Oncol. 1986;4(7):1094-1100.

36.    DeSimone JA, Guenova E, Carter JB, et al. Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013;69(1):61-65.

37.    Dummer R, Eichmuller S, Gellrich S, et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther. 2010;18(6):1244-1247.

38.    Kaplan EH, Rosen ST, Norris DB, Roenigk HH, Jr., Saks SR, Bunn PA, Jr. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990;82(3):208-212.

39.    Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006;132(1):3-12.

40.    Zinzani PL, Corradini P, Gallamini A, et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma. 2012;53(5):789-795.

41.    Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92(6):784-794.

42.    Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012;4(117):117ra117.

43.    Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma. 2009;50(12):1969-1976.

44.    Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72(9):1293-1298.

45.    Kaminetzky D, Hymes KB. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics. 2008;2(4):717-724.

46.    Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. 
J Clin Oncol. 2001;19(2):376-388.

47.    Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247-1252.

48.    Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007;13(8):2318-2322.

49.    Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410-5417.

50.    US Food and Drug Administration. FDA Approves Drug Treatment for Rare Cancer. Cutaneous T-cell lymphoma affects about 1,500 Americans annually. 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm189629.htm. Accessed April 22, 2013.

51.    Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003;98(5):993-1001.

52.    Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104(11):2437-2441.

53.    Akilov OE, Geskin L. Therapeutic advances in cutaneous T-cell lymphoma. Skin Therapy Lett. 2011;16(2):1-5.

54.    de Masson A, Beylot-Barry M, Bouaziz JD, et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014;99(3):527-534.

55.    Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012;19(3):236-244.

56.    Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479-484.

57.    Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600-1609.

58.    Valencak J, Raderer M. Treatment of primary cutaneous B-cell lymphomas: an overview. Eur J Clin Med Oncol. 2009;1(1):1-8.

59.    Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154-158.

60.    Penate Y, Hernandez-Machin B, Perez-Mendez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol. 2012;167(1):174-179.

61.    Grange F, Maubec E, Bagot M, et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol. 2009;145(3):329-330.

62.    Fenot M, Quereux G, Brocard A, Renaut JJ, Dreno B. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol. 2010;20(6):753-757.

63.    Morales AV, Advani R, Horwitz SM, et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol. 2008;59(6):953-957.

64.    Valencak J, Weihsengruber F, Rappersberger K, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol. 2009;20(2):326-330.

65.    Maza S, Gellrich S, Assaf C, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study. Leuk Lymphoma. 2008;49(9):1702-1709.